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Abstract:  Aim: The pathogenesis of deep venous thrombosis (DVT) involves an interaction between hereditary and   
acquired factors. Prothrombin gene mutation is one of the hereditary risk factors. We evaluated the frequency of the 
prothrombin gene mutation in patients with DVT and its relation to oral warfarin anticoagulant therapy response. 
Methods: Prothrombin gene mutation was looked for in 40 DVT patients with poor response to warfarin. The results were 
compared with 40 DVT patients with a normal response to warfarin and 30 healthy blood donors. Blood samples were 
also assessed for protein C, protein S, anti-thrombin III and anticardiolipin antibodies (ACA) levels. 
Results:  Prothrombin gene mutation was found in normal and poor DVT responders (6/40 and 13/40, respectively;   
p = NS) as well as in healthy controls (1/30). Patients with recurrent DVT or a family history of DVT were significantly 
(p<0.0001) more likely to have the prothrombin mutation than other DVT patients.  Non prothrombin abnormalities   
(protein C, anti-thrombin III and ACA) were more common in poor responders than controls (p<0.0037) as were ACA 
(p<0.034).  
Conclusions: Prothrombin gene mutation is present in several DVT patients, especially those with recurrent DVT or a 
family history of DVT. This mutation may contribute to a poor response to warfarin.  
Keywords: Deep venous thrombosis, gene mutation, prothrombin, warfarin. 
INTRODUCTION 
  Deep venous thrombosis (DVT) and its complications 
[pulmonary embolism and post-thrombotic syndrome) are 
not only common preventable causes of hospital death but 
also a source of substantial long-term morbidity [1]. 
  The pathogenesis of DVT involves an interaction be-
tween hereditary and acquired conditions [2-4]. Generally, 
DVT occurring in the setting of a recognized risk factor is 
defined as secondary, whereas that occurring in the absence 
of risk factors is termed primary or idiopathic [5]. 
  In primary DVT, tendency toward venous thrombosis 
could arise from hyperactive coagulation pathway, hypoac-
tive anticoagulant mechanisms, or hypoactive fibrinolysis [2, 
6]. With the identification of the well-characterized risk fac-
tors associated with secondary DVT, there is increasing in-
terest in the laboratory identification of primary thrombotic 
risk factors. Identification of these risk factors may affect 
treatment and identify other affected family members before 
the onset of symptoms. This could justify the use of prophy-
lactic anticoagulant therapy during high-risk periods [7].  
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  Over the past few years, studies have focused on the role 
of mutations in genes that encode proteins involving throm-
bosis pathways. Prothrombin (factor II) is one of these pro-
teins. It is the precursor of the serine protease thrombin, a 
key enzyme acting as a procoagulant, through platelet activa-
tion and the generation of fibrin and factors Va, VIIIa, and 
XIIIa, and subsequently as an anticoagulant, by activating 
circulating protein C [2, 6]. Therefore, regulation of throm-
bin activity is crucial for maintaining hemostatic balance [7]. 
The gene encoding prothrombin is 21-kb-long located on 
chromosome 11, position 11p11-q12 [8, 9]. The prothrombin 
gene is organized in 14 exons, separated by 13 introns with 
the 5 upstream untranslated (UT) region and the 3- UT   
region which may play regulatory roles in gene expression 
[6, 10]. One genetic variation in the 3-UT region of the 
prothrombin gene is the G to A transition at nucleotide   
position 20210, at or near the cleavage site of the mRNA 
precursor to which poly A is added [8]. This is termed as the 
factor II G 20210 A mutation. 
  In 1996, Poort et al. reported that the factor II G20210A 
mutation is associated with an increased risk of venous 
thrombosis [6]. Several studies confirmed this initial obser-
vation [10, 11]. 
  The prevalence of carriers of factor II G20210A mutation 
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Europeans the prevalence is nearly double (3%) [12]. In   
contrast, factor II G20210A mutation was found in only 1 of 
441 African Americans [13] and was completely absent 
among 231 Amerindians from Brazil and 210 Japanese   
subjects [11, 14]. Patients with this heterozygous gene muta-
tion have increased prothrombin levels and therefore, a 
thrombotic tendency [2]. 
  In this study we assessed the presence of the factor II 
G20210A mutation in DVT patients especially in those who 
showed poor response to warfarin therapy.  
PATIENTS AND METHODS  
  This is a prospective comparative study. The studied 
population included 80 patients with acute DVT and 30 
healthy blood donor controls of both sexes, residing in the 
Suez Canal area in Egypt. 
  Clinical diagnosis of acute DVT (Department of Surgery 
– Suez Canal University Hospital) was confirmed by Duplex 
scan. The Department of Surgery was also responsible for 
the initial and maintenance anticoagulation therapy. 
  Patients with previous history of DVT (in the same or 
other site) were defined as recurrent DVT, and those with 
DVT history in first degree relatives were defined as having 
a positive family history. 
  Data collection included other DVT risk factors such as: 
complete bed rest for more than 3 days, recent surgery (tho-
racic, abdominal, pelvic or major lower extremity orthopedic 
procedure within the previous week), major trauma (fracture 
[e.g. pelvic, femoral or tibial), spinal cord injuries or associ-
ated with major venous injury], use of contraceptive pills   
or hormone replacement therapy and the coexistence of   
varicose veins or neoplasia [5]. Drug history (specially inter-
acting with anticoagulants) was checked. 
  Exclusion criteria: Patients receiving drugs that interact 
with warfarin were excluded, as well as pregnant females   
as oral anti-coagulants are contraindicated during pregnancy 
[5].  
  All patients received low molecular weight heparin 
enoxaparin (Clexane) 1 mg/kg/12h subcutaneously for 5 
days, with a dose of 5 mg for 2 days. Warfarin dose was  
adjusted to reach International Normalized Ratio (INR) of 
2.0-3.0 [5].  
  The study population was divided into 2 groups: the first 
group was the Poor Responders, defined as the DVT patients 
who fail to reach the intended level of INR with the usual 
dose of warfarin (usually 1 - <9 mg/day), those patients   
usually require more than 9 mg/day to reach the therapeutic 
INR level [15-19]; we recruited 40 patients during the study 
period. This first group was compared with a second group 
of 40 randomly selected DVT Normal Responders, defined 
as those who reached an INR between 2 and 3. In addition, a 
control group of 30 healthy blood donors living in the same 
area were randomly selected; none of them had a previous 
history of DVT. 
  Factor II gene mutation, protein S, protein C, anti-
thrombin III and anti-cardiolipin antibodies were assessed in 
all DVT patients and controls. Prothrombin time and INR 
were assessed in DVT patients before induction of therapy. 
Detection of Factor II G20210A Mutation by Real-time 
PCR  
  Detection was done by real-time PCR assay [20] using 
the LightCycler prothrombin G20210A mutation detection 
kit (Roche Molecular Biochemicals, Catalog No. 2 236 842) 
[21]. The 165 bp fragment of prothrombin gene is monitored 
by adjacent hybridization probes that are designed to bind on 
1 amplicon strand. The 3’ end of 1 probe is labeled with 
fluorescein (FLU), whereas the 5’ end of an adjacent probe 
is labeled with LightCycler-Red640 (Roche Molecular Bio-
chemicals) as the anchor probe. When both probes hybridize 
in close proximity, only after hybridization to the template 
DNA, fluorescence resonance energy transfer (FRET)   
occurs, producing a specific fluorescence emission of   
LC-Red as a result of FLU excitation. Increasing the tem-
perature during fluorescence reading yields a temperature/ 
fluorescence curve from which the melting point of the 
probe can be derived. When the appropriate conditions are 
chosen, the mismatch under the detection probe caused by a 
single point mutation leads to a substantial decrease in the 
melting point of the probe [16]. DNA was isolated from 200 
L of EDTA-treated blood with the QIAamp DNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. The 
DNA was eluted in 200 L of elution buffer and stored   
at -20 °C. PCR reactions were performed in a final volume 
of 20 L in the LightCycler glass capillaries, which   
contained 2 L of 1x Light Cycler prothrombin G20210A 
mutation detection mix, 2L of 1x Light Cycler prothrombin 
G20210A mutation reaction mix, and 5 L of DNA solution. 
PCR-grade water was added to a final volume of 20 L. 
Each run included a positive control, which is heterozygous 
DNA control, and negative control, which is PCR-grade   
water.  
Statistical Analysis  
  Results are expressed as mean and proportion values   
for baseline characteristics for patients and control subjects. 
Differences were tested with the Student’s t and Fisher exact 
tests using SPSS version15.  
RESULTS 
  Sex and age distribution in the studied groups are shown 
in Table 1. Median age in the 3 groups was similar. 
  Regarding the site of DVT, the superficial femoral vein 
was the affected in 35% and 30 % of the poor responders and 
normal responders, respectively, followed by the popliteal 
vein in 25% and 27.5 % and only 3% and 5 % of the patients 
had iliac DVT. In the remaining 37% of the poor responders 
and 37.5% of the normal responders the affected vein was 
either the anterior or the posterior tibial vein. 
  Forty five percent of the poor responders and 40% of   
the normal responders had no risk factors. In the remaining 
patients of both groups, these risk factors were comparable 
and not significant. Except for recurrent DVT which was 
higher in the poor responders group (25%) than the normal 
responders (10%); (Table 2). 
  The laboratory results of the inherited and acquired 
thrombophilic risk factors in the studied groups are shown  
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were observed only in the poor responders group. The non 
Prothrombin mutation abnormalities (Protein C, anti-
thrombin III and ACA) were present in 10 poor responders 
vs 0 controls (p = 0.0037). ACA was significantly higher in 
poor responder than in the control subjects (p<0.034). Re-
garding the prothrombin gene mutation, homozygous muta-
tion was observed in only 1 patient in the poor responders 
group. Heterozygous mutation of the PT gene was observed 
in the 3 studied groups, but it was higher in the poor re-
sponders than in the normal responder and control groups 
(12, 6 and 1 subject, respectively). The difference between 
the poor responders and the normal controls was highly   
significant p=0.002 (Table 3). This table also shows the   
distribution of other thrombophilic risk factors.  
 Table  4 shows that the positive factor II G20210A   
mutation was significantly (p<0.0001) more frequent among 
patients with a history of recurrent DVT or a positive family 
history of DVT compared with the other DVT patients. 
DISCUSSION 
  On treating patients with acute DVT, we faced patients 
who did not show the usual elevation of PT/INR in response 
to usual doses of warfarin. This may reflect an elevated 
prothrombin level due to a genetic mutation [19]. This muta-
tion may, not only, cause the low response to oral anticoagu-
lant, but may also contribute to the recent and future   
episodes of DVT [2]. Patients with this gene mutation may 
need higher doses of warfarin (to reach INR target levels) for 
longer periods [15, 22]. 
  In the present study, analysis of risk factors showed that 
recurrent DVT was numerically higher but not significant in 
the poor responders than for the normal responders. Family 
history was also higher in the poor responders, but not sig-
nificantly so. This may reflect the presence of a specific risk 
factor for DVT in the poor responders group. The rest of the 
risk factors showed similarity with no significant differences 
between the poor and normal responders. This agrees with 
the fact that these are recognised risk factors that may cause 
DVT in all patients. It also suggests that multiple risk factors 
might be necessary before clinically evident DVT develops 
even in patients with thrombotic gene mutation [23]. 
  We detected the factor II G20210A mutation in 20 indi-
viduals in our study population (n=110). Homozygous muta-
tion was found in only 1 patient in the poor responders 
group, while heterozygous mutation was found in the 3 
groups. The gene mutation was recognized in 1(3.4%) of the 
normal population, which agrees with others who found this 
mutation in 1%, 1.7% and 3% of the normal Pakistan, 
Northern and Southern European population, respectively 
[11, 12, 24]. However, our finding only represents the 30 
studied healthy blood donors. Larger studies are needed to 
define the exact prevalence in our community.  
  Heterozygous gene mutation was found in 30% of the 
poor responders and 15% of the normal responders. This 
supports the concept that factor II G20210A mutation may 
cause high prothrombin levels [6] which may, in turn, be 
responsible for resisting oral anticoagulants. The presence   
of the same mutation in some normal responders may be 
Table 1.  Sex and Age Distribution in the Deep Venous Thrombosis (DVT) Patients and Control Subjects 
  Poor DVT Responders (n = 40)  Normal DVT Responders (n = 40)  Control Subjects (n = 30) 
Male/Female 16/24  18/22  18/12 
Median (range) age in years   41.5 (22-61)  42.5 (20-65)  43.1 (20-48) 
No differences were significant.  
 
Table 2.  Risk Factors in the Deep Venous Thrombosis (DVT) Patients 
Risk Factor  Poor DVT Responders (n)  Normal DVT Responders (n)  P  
None 18  16  NS 
Prolonged bed rest  0  0   
Recent surgery  8  6  NS 
Major trauma  6  4  NS 
Contraceptive pill /hormone therapy  2  4  NS 
Varicose veins  0  0   
Neoplasia 2  2  NS 
Recurrent DVT  10  4  NS  
Family history  6  4   NS 
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explained by the presence of different degrees of mutation 
that did not clinically affect the prothrombin levels. This 
gene mutation with less clinical significance was previously 
suggested [25]. 
  Our findings agree with previous reports that suggested 3 
to 6 fold higher risk of developing DVT in prothrombin gene 
mutation patients than the normal population [2, 9]. This also 
points to the importance of screening the patient’s family as 
they may be at increased risk of developing DVT. However, 
the interpretation of our results is limited by the small   
sample size and selection bias.  
  Protein C, anti-thrombin III and ACA abnormalities were 
found in more poor responders DVT patients than controls. 
Bernd  et al. [26] suggested that special caution is needed 
when giving anticoagulants to patients with protein C defi-
ciency. Because protein C is a vitamin K dependent factor, 
the administration of warfarin could lead to sudden decrease 
in protein C before any noticeable decrease in coagulation 
factors. This could cause enhanced thrombosis and diffuse 
skin necrosis. Also, ACA was significantly more common  
in poor responders than control subjects. It has also been 
suggested that patients with ACA and venous thromboem-
bolism are resistant to usual intensities of warfarin therapy, 
which may prompt more intense anticoagulation of these 
patients. However,  no substantial difference was seen   
between the ACA-positive and ACA-negative patients, for 
several thromboplastins [27]. 
  To add to the dilemma of DVT and genetic disorders, 
pharmacogenetic studies should be ideally be carried out in 
DVT patients before warfarin anticoagulant therapy as Le-
ung et al. 2007 [28] reported that patients with Cytochrome 
P-450 CYP2C9*2, CYP2C9*3, or VKORC1*2 genotype (c.-
1639G>A) in presence of Factor V Leiden and/or factor II 
G20210A mutation require significantly reduced doses, and 
are at a higher risk of serious bleeding. 
  In conclusion, our findings suggest that factor II 
G20210A mutation may be more common in DVT patients 
who are poor responders to warfarin. Factor II G20210A 
mutation was more common in patients with recurrent DVT 
or positive family history of DVT.  
Table 3.  Distribution of the Inherited and Acquired Thrombophilic Risk Factors Alone or in Combination with Prothrombin 
Gene Mutation 
Risk Factors  Poor DVT Responders  
(n = 40) 
Normal DVT Responders  
(n = 40) 
P 
Control Subjects 
(n = 30) 
Protein C deficiency   2  0  NS  0 
Protein S deficiency   0  0  NS  0 
Anti - thrombin III   2  0  NS  0 
Homo FII A mutation   1  0  NS  0 
Hetero FII A mutation   12  6  0.002**
  1 
ACA   6  4  0.034*  0 
F II A + Anti-thrombin III   0  0  NS  - 
F II A + Protein C   1  0  NS  - 
F II A + Protein S   1  0  NS  - 
F II A + ACA   2  2   NS  - 
* Poor DVT responders vs control subjects 
** FII A mutation in poor DVT responders vs control subjects; includes the homozygous mutation in the poor responders 
NS = not significant 
ACA = anticardiolipin antibodies 
F II A = factor II G20210A mutation.  
 
Table 4.  Relation Between Factor II G20210A Mutation and Recurrent or Family History of Deep Venous Thrombosis (DVT) 
  Recurrent DVT  Non – Recurrent DVT  P  
Mutation +ve  12  7  <0.0001 
Mutation -ve  2  59   
  +ve Family History  -ve Family History   
Mutation +ve   8  11  <0.0001 
Mutation -ve   2  59   Prothrombin Gene G20210A Mutation in Acute Deep Venous Thrombosis  The Open Cardiovascular Medicine Journal, 2009, Volume 3    151 
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